keyword
MENU ▼
Read by QxMD icon Read
search

Palivizumab

keyword
https://www.readbyqxmd.com/read/29149439/trends-in-utilization-of-outpatient-respiratory-syncytial-virus-prophylaxis-with-palivizumab-among-medicaid-and-commercially-insured-infants
#1
Melissa Pavilack, Robert A Clifford, Tara Gonzales, Amanda M Kong, Sally Wade, Kimmie K McLaurin
INTRODUCTION: Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes outpatient palivizumab utilization trends and characterizes high-risk infants receiving palivizumab within Medicaid- and commercially insured populations. METHODS: Infants born July 1, 2003 through June 30, 2013 were identified in the MarketScan(®) Multistate Medicaid and Commercial claims databases...
November 17, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29130355/adherence-and-outcomes-a-systematic-review-of-palivizumab-utilization
#2
Sophie K Wong, Abby Li, Krista L Lanctôt, Bosco Paes
Palivizumab is a humanized monoclonal antibody used for respiratory syncytial virus (RSV) prophylaxis. RSV is the primary cause of lower respiratory tract infection in children aged <2 years, and can give rise to high-burden hospitalization and respiratory complications in later life. Adherence to a monthly dosing regimen, both in timing and injection number, is essential to sustain therapeutic levels of palivizumab and maintain protective status. Deviation from the approved dosing schedule may reduce the efficacy of palivizumab and increase the risk of breakthrough RSV infection and hospitalization...
November 13, 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/29118126/respiratory-syncytial-virus-rsv-targeting-the-g-protein-provides-a-new-approach-for-an-old-problem
#3
Ralph A Tripp, Ultan F Power, Peter J M Openshaw, Lawrence M Kauvar
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI) annually affecting >2 million children in the US <5 years old. In the elderly (>65 years old), RSV results in ∼175,000 hospitalizations annually in the US with worldwide incidence ∼34 million. There is no approved RSV vaccine and treatments are limited. Recently, a Phase 3 trial in the elderly using a recombinant RSV F protein vaccine failed to meet its efficacy objectives, namely prevention of moderate-to-severe RSV-associated LRTI and reduced incidence of acute respiratory disease...
November 8, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29106671/palivizumab-for-infants-%C3%A2-29-weeks-in-hong-kong-without-a-clear-cut-season-for-respiratory-syncytial-virus-infection-a-cost-effectiveness-analysis
#4
Shing-Yan Robert Lee, Ka Li Kwok, Daniel Kwok Keung Ng, Kam Lun Hon
Aim: To evaluate the cost-effectiveness of palivizumab prophylaxis for premature infants born <29 weeks in Hong Kong. Method: We evaluated the hospitalization rate for respiratory syncytial virus (RSV) infection within the first 12 months of discharge of a cohort of preterm infants born between 2010 and 2014 at two local hospitals. Results: In total, 40 of 135 infants were given palivizumab. The hospitalization rate for premature infants <29 weeks was reduced from 15...
November 2, 2017: Journal of Tropical Pediatrics
https://www.readbyqxmd.com/read/29096027/impact-of-an-antimicrobial-stewardship-policy-to-restrict-palivizumab-use
#5
Torsten Joerger, Shannon Chan, Sanjeev K Swami, Lori K Handy
No abstract text is available yet for this article.
October 31, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/29042834/improving-palivizumab-compliance-rough-a-pharmacist-managed-rsv-prevention-clinic
#6
Jennifer W Chow, Michael F Chicella, Anthony M Christensen, Carolyn S Moneymaker, John Harrington, James E Dice
OBJECTIVES: Palivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. While palivizumab is more effective if used correctly, compliance with the monthly dosing is suboptimal. We established a pharmacist-managed RSV prevention clinic in an effort to improve compliance. The primary objective of this study was to determine the impact of a pharmacist-managed RSV prevention clinic on palivizumab compliance...
September 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29041909/cost-utility-analysis-of-palivizumab-for-respiratory-syncytial-virus-infection-prophylaxis-in-preterm-infants-update-based-on-the-clinical-evidence-in-spain
#7
M Sanchez-Luna, R Burgos-Pol, I Oyagüez, J Figueras-Aloy, M Sánchez-Solís, F Martinón-Torres, X Carbonell-Estrany
BACKGROUND: This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32(day 1)-35(day 0)weeks of gestational age -wGA-) in Spain. METHODS: A decision-tree model was developed to compare health benefits (Quality Adjusted Life Years-QALYs) and costs of palivizumab versus a non-prophylaxis strategy over 6 years. A hypothetical cohort of 1,000 preterm infants, 32(day 1)-35(day 0) wGA (4...
October 17, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29021302/development-of-a-high-throughput-respiratory-syncytial-virus-fluorescent-foci-based-microneutralization-assay
#8
Cindy Shambaugh, Sarieh Azshirvani, Li Yu, Jared Pache, Stacie L Lambert, Fengrong Zuo, Mark T Esser
Neutralizing antibodies specific for respiratory syncytial virus (RSV) represent a major protective mechanism against RSV infection as demonstrated by the efficacy of the immune-prophylactic monoclonal antibody, Palivizumab, in preventing RSV associated lower respiratory tract infections in premature infants. Accordingly, the RSV neutralization assay has become a key functional method to assess the neutralizing activity of serum antibodies in pre-clinical animal models, epidemiology studies and clinical trials...
October 11, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/29019703/imbalance-in-level-of-tobacco-smoke-exposure-between-groups-likely-explains-the-effect-of-palivizumab-on-subsequent-wheezing
#9
Harold J Farber
No abstract text is available yet for this article.
October 11, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29019701/precise-gestational-age-definitions-needed-for-palivizumab-prophylaxis-in-preterm-infants
#10
Shilpi Chabra
No abstract text is available yet for this article.
October 11, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28987219/role-of-viral-infections-in-the-development-and-exacerbation-of-asthma-in-children
#11
REVIEW
Tuomas Jartti, James E Gern
Viral infections are closely linked to wheezing illnesses in children of all ages. Respiratory syncytial virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly detected in wheezing children thereafter. Severe respiratory illness induced by either of these viruses is associated with subsequent development of asthma, and the risk is greatest for young children who wheeze with RV infections. Whether viral illnesses actually cause asthma is the subject of intense debate...
October 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28950031/alternative-viewpoint-efficacy-and-effectiveness-of-respiratory-syncytial-virus-immunoprophylaxis-in-children-with-cystic-fibrosis-an-unsolved-question-with-more-to-be-asked
#12
Rees L Lee, Rebekah F Brown, Tebeb Gebretsadik, Tina V Hartert, William D Dupont, Pingsheng Wu
No abstract text is available yet for this article.
September 26, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28946159/palivizumab-the-effects-of-prophylactic-immunization-on-the-occurrence-of-infections-caused-by-the-respiratory-syncytial-virus
#13
Marjana Jerkovic Raguz, Jerko Brzica, Ivana Grgic
Aim The aim of this research is to analyze the characteristics of children immunized during immunization season, and their readmission to hospital due to infections of the respiratory tract in the period from 2008 to 2016. Method The retrospective cohort study included 101 children. The test group consists of infants who met the strict criteria for immunization. The national guidance was determined on the basis of earlier research and recommendations by the AAP. All the children who had been readmitted for hospitalization were quickly tested for RSV...
September 2017: Klinische Pädiatrie
https://www.readbyqxmd.com/read/28926860/palivizumab-for-prophylaxis-of-respiratory-syncytial-virus-infections-in-preterm-neonates
#14
Ludwig Gortner
No abstract text is available yet for this article.
September 2017: Klinische Pädiatrie
https://www.readbyqxmd.com/read/28895096/palivizumab-prophylaxis-against-respiratory-syncytial-virus-infection-in-children-with-immunocompromised-conditions-or-down-syndrome-a-multicenter-post-marketing-surveillance-in-japan
#15
Tomoko Kashiwagi, Yukiko Okada, Ken Nomoto
OBJECTIVE: The aim of this study was to assess the safety and effectiveness of palivizumab for the prevention of lower respiratory tract infection (LRI) caused by respiratory syncytial virus (RSV) in children with immunocompromised conditions or Down syndrome. METHODS: In this multicenter, post-marketing surveillance study (December 2013 to December 2015), children aged ≤24 months with immunocompromised conditions or Down syndrome (without hemodynamically significant congenital heart disease) receiving palivizumab immunoprophylaxis during two RSV seasons were observed until 30 days after the final palivizumab injection...
September 11, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28889192/the-economic-impact-of-prematurity-and-bronchopulmonary-dysplasia
#16
María Álvarez-Fuente, Luis Arruza, Marta Muro, Carlos Zozaya, Alejandro Avila, Paloma López-Ortego, Carmen González-Armengod, Alba Torrent, Jose Luis Gavilán, María Jesús Del Cerro
Bronchopulmonary dysplasia (BPD) is one of the most serious chronic lung diseases in infancy and one of the most important sequels of premature birth (prevalence of 15-50%). Our objective was to estimate the cost of BPD of one preterm baby, with no other major prematurity-related complications, during the first 2 years of life in Spain. Data from the Spanish Ministry of Health regarding costs of diagnosis-related group of preterm birth, hospital admissions and visits, palivizumab administration, and oxygen therapy in the year 2013 were analyzed...
December 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28887119/respiratory-syncytial-virus-associated-hospitalizations-in-children-with-congenital-diaphragmatic-hernia
#17
Bernhard Resch, Krisztina Liziczai, Friedrich Reiterer, Thomas Freidl, Michaela Haim, Berndt Urlesberger
BACKGROUND: To evaluate the risk of RSV infection in infants and children with congenital diaphragmatic hernia (CDH) over two consecutive RSV seasons. METHODS: Retrospective, single-center cohort study from southern Austria including infants with CDH born between 1993 and 2012. Infants were retrieved by searching via ICD-10 codes Q79.0 and Q79.1 and by using a local electronic database. Children were followed over 2 years of life including at least two consecutive RSV seasons (November to April)...
August 16, 2017: Pediatrics and Neonatology
https://www.readbyqxmd.com/read/28867684/neutralizing-epitopes-of-rsv-and-palivizumab-resistance-in-japan
#18
Koichi Hashimoto, Mitsuaki Hosoya
Respiratory Syncytial Virus (RSV) is one of the most important viral pathogen related to acute lower respiratory infection in young children. The virus surface envelope contains the G, F, and SH proteins as spike proteins. The F protein is considered to be a major antigenic target for the neutralizing (NT) epitope as only the F protein is essential for cell infection among the three viral envelope proteins, and it is more highly conserved than the G protein. Recently, four antigenic targets related to NT activity have been reported;site I, site II, site IV, and site zero (0)...
September 1, 2017: Fukushima Journal of Medical Science
https://www.readbyqxmd.com/read/28813765/bronchiolitis-in-infants-and-children
#19
Alexandra Schaller, Carl S Galloway
Bronchiolitis is among the most common illnesses in infants and children, and is the most common cause for hospitalization in infants in the U.S. This illness can be caused by many viruses, most commonly respiratory syncytial virus. It is diagnosed clinically by history and physical exam findings, with a narrow role for ancillary testing. Management is supportive, with medications demonstrating limited utility in multiple studies. Preventive measures include hand hygiene, breastfeeding, avoiding tobacco smoke exposure, and isolation precautions for hospitalized patients...
June 2017: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/28783400/is-immunoprophylaxis-with-palivizumab-justified-for-respiratory-syncytial-virus
#20
Siba P Paul, Georgina M Ball
No abstract text is available yet for this article.
August 2, 2017: British Journal of Hospital Medicine
keyword
keyword
44503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"